Biosimilar Contract Manufacturing Market is predicted to reach USD 26.1 Billion at a CAGR of 18.90% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Biosimilar Contract Manufacturing Market”

Global Biosimilar Contract Manufacturing Market Highlights

The global Biosimilar Contract Manufacturing market is accounted to register a CAGR of 18.90% during the forecast period and is estimated to reach USD 26.1 Billion by 2032.

The primary market factors boosting market expansion are the increasing usage of biosimilars in the treatment of diseases like cancer, autoimmune disorders, blood disorders, and others, as well as their cheaper cost when compared to biologics. The increasing usage of biosimilars in the treatment of diseases like cancer, autoimmune disorders, blood disorders, and others, as well as their reduced cost as compared to biologics, are two major factors driving the market.

Key Players

MRFR recognizes the following companies as the key players in the global Biosimilar Contract Manufacturing market— Boehringer Ingelheim GmbH, Lonza, Catalent Inc., Biocon, IQVIA Inc., AGC Biologics., Samsung Biologics., WuXi Biologics., Element Materials Technology, Rentschler Biopharma SE, Avid Bioservice, Inc., Alcami Corporation, Inc., Fujifilm Kyowa Kirin Biologics Co., Ltd., Thermo Fisher Scientific Inc., and Almac Group.

Segment Analysis

The global Biosimilar Contract Manufacturing market has been segmented based product, production technology, and application.

On the basis of product, the market is segmented into recombinant non-glycosylated proteins and recombinant glycosylated proteins. In 2022, the sector of recombinant non-glycosylated proteins dominated the world market. Recombinant non-glycosylated proteins include insulin, interferon, granulocyte colony-stimulating factors (G-CSFs), and human growth hormone.

Based on production technology, the global Biosimilar Contract Manufacturing market has been segmented into Production Technology, includes mammalian and non-mammalian. In 2022, the mammalian category led the global market for biosimilar contract manufacturing. This is due to the important benefit of using mammalian cells for protein expression, which allows for the creation of mammalian proteins with the correct post-translational modifications that provide a native structure.

Based on application, the global Biosimilar Contract Manufacturing market has been segmented into oncology, blood disorders, growth hormonal deficiency, chronic & autoimmune disorders, rheumatoid arthritis, and others. In 2022, the oncology category dominated the world market. This is due to the high incidence of cancer, which includes liver, colon, lung, stomach, breast, and blood cancers.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Biosimilar Contract Manufacturing Market Research Report

Regional Analysis

The global Biosimilar Contract Manufacturing market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Biosimilar Contract Manufacturing market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Biosimilar Contract Manufacturing market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Biosimilar Contract Manufacturing market comprises of Middle East, Africa, and Latin America.

In 2022, the North American Biosimilar Contract Manufacturing Market had a sizable portion of the market. The recent high number of biosimilar drug approvals, which is also promoting the region's development, has made it easier for people in the area to take biosimilar pharmaceuticals on a large scale.

In 2022, the Europe Biosimilar Contract Manufacturing market held a 45.80% share of the market. This is made possible by the existence of significant biopharmaceutical contract development and manufacturing firms like Lonza, Boehringer Ingelheim GmbH, Rentschler Biopharma SE, and Element Materials Technology as well as a regulatory framework for biosimilars that is clearly defined.

From 2023 to 2032, the Asia Pacific Biosimilar Contract Manufacturing market is anticipated to experience rapid growth. The increasing prevalence of chronic diseases and the growing need for less expensive therapeutic items are the key forces behind the region's growth. The increasing importance of contract projects in countries like China, India, and South Korea is another important factor that is anticipated to considerably contribute to the region's growth.

Furthermore, the rest of the world's Biosimilar Contract Manufacturing market is divided into the Middle East, Africa, and Latin America. LATAM countries offer a large patient population and growing demand for biologics. Additionally, the region's lower manufacturing costs make it an attractive destination for biosimilar contract manufacturing, both for domestic and international companies.

Key Findings of the Study

• The global Biosimilar Contract Manufacturing market is expected to reach USD 26.1 Billion by 2032, at a CAGR of 18.90% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market. increasing prevalence of chronic diseases and the growing need for less expensive therapeutic items are the key forces behind the region's growth.


• Based on application, the transportation segment was attributed to holding the largest market in 2022, with an approximate market share of 45–65%.


• Boehringer Ingelheim GmbH, Lonza, Catalent Inc., Biocon, IQVIA Inc., AGC Biologics., Samsung Biologics., WuXi Biologics., Element Materials Technology, Rentschler Biopharma SE, Avid Bioservice, Inc., Alcami Corporation, Inc., Fujifilm Kyowa Kirin Biologics Co., Ltd., Thermo Fisher Scientific Inc., and Almac Group